|

Lutetium Lu 177 Vipivotide Tetraxetan Clinical Trials

10 actively recruiting trials across 8 locations

No change since August 2026

Also known as: 177Lu-PSMA-617, 177Lu-labeled PSMA-617, AAA 617, AAA-617, AAA617 +5 more

Pipeline

Phase 1: 3Phase 2: 6Phase 3: 1

Top Sponsors

  • University of Washington2
  • Jonsson Comprehensive Cancer Center2
  • Janssen Research & Development, LLC2
  • Alliance for Clinical Trials in Oncology2
  • Fred Hutchinson Cancer Center1

Indications

  • Cancer10
  • Stage IVB Prostate Cancer AJCC v87
  • Castration-Resistant Prostate Carcinoma3
  • Metastatic Castration-Resistant Prostate Adenocarcinoma2
  • Metastatic Castration-Resistant Prostate Carcinoma2

Los Angeles, California2 trials

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Seattle, Washington2 trials

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama1 trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Anchorage, Alaska1 trial

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Providence Alaska Medical Center

Phase 3

Duarte, California1 trial

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1

San Francisco, California1 trial

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

University of California San Francisco

Phase 2

Aurora, Colorado1 trial

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

University of Colorado Anschutz Medical Campus

Phase 1

Sarasota, Florida1 trial

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.